These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 23143965)

  • 1. [Ocular myasthenia revealed by risedronate].
    Sanchez-Ayaso PA; Garcia-Munozguren S; Salmeron MP
    Rev Neurol; 2012 Nov; 55(10):639-40. PubMed ID: 23143965
    [No Abstract]   [Full Text] [Related]  

  • 2. Risedronate induced transient ocular myasthenia.
    Raja V; Sandanshiv P; Neugebauer M
    J Postgrad Med; 2007; 53(4):274-5. PubMed ID: 18097124
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous vasculitis induced by risedronate.
    Belhadjali H; Slim R; Aouam K; Youssef M; Zili J
    Allergy; 2008 Oct; 63(10):1405. PubMed ID: 18782119
    [No Abstract]   [Full Text] [Related]  

  • 4. Squamous metaplasia of the conjunctiva: a previously unrecognized adverse effect of risedronate sodium.
    Geneva II; Eagle RC; Barker-Griffith A; Stefanyszyn M; Weisenthal R
    JAMA Ophthalmol; 2013 Feb; 131(2):249-51. PubMed ID: 23411897
    [No Abstract]   [Full Text] [Related]  

  • 5. Simultaneous bilateral subtrochanteric fractures following risedronate therapy.
    Ovaska MT; Mäkinen TJ; Madanat R
    J Orthop Sci; 2011 Jul; 16(4):467-70. PubMed ID: 21779886
    [No Abstract]   [Full Text] [Related]  

  • 6. Monthly risedronate (Actonel) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2008 Sep; 50(1294):69-70. PubMed ID: 18772843
    [No Abstract]   [Full Text] [Related]  

  • 7. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
    Kishimoto H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
    [No Abstract]   [Full Text] [Related]  

  • 8. Risedronate-induced arthritis.
    Yemisci OU; Yalbuzdag SA; Karatas M
    J Clin Rheumatol; 2010 Jun; 16(4):168-9. PubMed ID: 20414126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate-induced intravascular haemolysis complicated by acute tubular necrosis.
    Ozkurt ZN; Güliter S; Keleş I; Keleş H
    Clin Rheumatol; 2005 Nov; 24(6):665-6. PubMed ID: 15902526
    [No Abstract]   [Full Text] [Related]  

  • 10. Symptomatic hypocalcemia due to oral risedronate therapy.
    Dogru T; Sonmez A; Tasci I; Genc H
    Indian J Med Sci; 2005 Dec; 59(12):542-3. PubMed ID: 16385174
    [No Abstract]   [Full Text] [Related]  

  • 11. [FACT study].
    Tanaka I; Oshima H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():280-5. PubMed ID: 18161120
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential adverse effects.
    Scully C
    Br Dent J; 2006 Feb; 200(3):153. PubMed ID: 16474361
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
    Racewicz AJ; Schofield PJ; Cahall DL; Cline GA; Burgio DE
    Curr Med Res Opin; 2007 Dec; 23(12):3079-89. PubMed ID: 17971285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
    Qiu S; Phipps RJ; Ebetino FH; Palnitkar S; Sudhaker Rao D
    Calcif Tissue Int; 2010 Nov; 87(5):392-7. PubMed ID: 20809096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profound refractory hypocalcemia after thyroidectomy in a patient receiving chronic oral bisphosphonate therapy.
    Richmond BK
    Am Surg; 2005 Oct; 71(10):872-3. PubMed ID: 16468539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Osteoporosis management in general practice. Preventing spontaneous bone fractures].
    MMW Fortschr Med; 2010 Jul; 152(25-27):54-5. PubMed ID: 20672666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.